Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
Author(s) -
Agbaji Oche O.,
Abah Isaac O.,
Ebonyi Augustine O.,
Gimba Zumnan M.,
Abene Esla E.,
Gomerep Simji S.,
Falang Kakjing D.,
Anejo-Okopi Joseph,
Agaba Patricia A.,
Ugoagwu Placid O.,
Agaba Emmanuel I.,
Imade Godwin E.,
Sagay Atiene S.,
Okonkwo Prosper,
Idoko John A.,
Kanki Phyllis J.
Publication year - 2019
Publication title -
journal of the international association of providers of aids care (jiapac)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 31
eISSN - 2325-9582
pISSN - 2325-9574
DOI - 10.1177/2325958218821963
Subject(s) - medicine , interquartile range , regimen , cohort , renal function , tenofovir alafenamide , tenofovir , odds ratio , emtricitabine , logistic regression , antiretroviral therapy , human immunodeficiency virus (hiv) , viral load , immunology
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART).Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34).Conclusion: Long-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDF-based regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide–based regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom